Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1135290.RAx22z0QD7Ex3JxMxZccPTpv744R19v82FtsChXtbp9bc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1135290.RAx22z0QD7Ex3JxMxZccPTpv744R19v82FtsChXtbp9bc130_assertion type Assertion NP1135290.RAx22z0QD7Ex3JxMxZccPTpv744R19v82FtsChXtbp9bc130_head.
- NP1135290.RAx22z0QD7Ex3JxMxZccPTpv744R19v82FtsChXtbp9bc130_assertion description "[On the basis of preclinical data suggesting synergy of HER2 inhibition and mTOR inhibition in breast and lung cancer models, we conducted a phase I combination study of neratinib, a small-molecule irreversible pan-HER tyrosine kinase inhibitor, and temsirolimus, an mTOR inhibitor, in patients with advanced solid tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1135290.RAx22z0QD7Ex3JxMxZccPTpv744R19v82FtsChXtbp9bc130_provenance.
- NP1135290.RAx22z0QD7Ex3JxMxZccPTpv744R19v82FtsChXtbp9bc130_assertion evidence source_evidence_literature NP1135290.RAx22z0QD7Ex3JxMxZccPTpv744R19v82FtsChXtbp9bc130_provenance.
- NP1135290.RAx22z0QD7Ex3JxMxZccPTpv744R19v82FtsChXtbp9bc130_assertion SIO_000772 24323026 NP1135290.RAx22z0QD7Ex3JxMxZccPTpv744R19v82FtsChXtbp9bc130_provenance.
- NP1135290.RAx22z0QD7Ex3JxMxZccPTpv744R19v82FtsChXtbp9bc130_assertion wasDerivedFrom befree-2016 NP1135290.RAx22z0QD7Ex3JxMxZccPTpv744R19v82FtsChXtbp9bc130_provenance.
- NP1135290.RAx22z0QD7Ex3JxMxZccPTpv744R19v82FtsChXtbp9bc130_assertion wasGeneratedBy ECO_0000203 NP1135290.RAx22z0QD7Ex3JxMxZccPTpv744R19v82FtsChXtbp9bc130_provenance.